Ionis announces positive topline results from pivotal study of zilganersen in Alexander diseaseBusiness Wire • 09/22/25
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)Business Wire • 09/19/25
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseasesBusiness Wire • 09/12/25
Ionis: Recent Approvals, Upcoming Catalysts To Spur Strong Upside (Rating Upgrade)Seeking Alpha • 09/11/25
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman SyndromeZacks Investment Research • 09/10/25
Ionis Pharmaceuticals, Inc. (IONS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough StatusBenzinga • 09/09/25
Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndromeBusiness Wire • 09/09/25
Ionis Pharmaceuticals, Inc. (IONS) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)Seeking Alpha • 09/08/25
Ionis Pharmaceuticals, Inc. (IONS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeeking Alpha • 09/04/25
IONS Hits 52-Week High on Tryngolza's Success in Lowering TriglycerideZacks Investment Research • 09/03/25
Ionis Pharmaceuticals, Inc. (IONS) Positive CORE And CORE2 Topline Results (Transcript)Seeking Alpha • 09/02/25
Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis ReductionBenzinga • 09/02/25
Ionis Pharma Hits The 'Bull Case,' 'Blue Sky' In Lowering Triglycerides. Shares Launch.Investors Business Daily • 09/02/25
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)Business Wire • 09/02/25
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedemaBusiness Wire • 08/21/25
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 OutlookZacks Investment Research • 07/31/25